Citicoline and PRP in the Treatment of Glaucoma, Optic Nerve Atrophy, and Retinopathy
Citicoline and PRP in the Treatment of Glaucoma, Optic Nerve Atrophy, and Retinopathy: Modern Vision Restoration Methods
Ophthalmic neurodegenerative diseases such as glaucoma, optic nerve atrophy, diabetic retinopathy, and anterior ischemic optic neuropathy (AION) are serious conditions that lead to progressive vision loss and a significant decline in patients’ quality of life. Traditional treatment methods often fail to provide complete restoration of visual functions, prompting the search for new therapeutic approaches.
Glaucoma is a chronic disease characterized by increased intraocular pressure, leading to optic nerve damage and gradual vision loss.
Optic nerve atrophy is a condition in which the degeneration of optic nerve fibers occurs, resulting in vision deterioration up to complete blindness.
Diabetic retinopathy is a complication of diabetes mellitus, characterized by damage to the retinal blood vessels, potentially leading to vision loss.
Anterior ischemic optic neuropathy (AION) is an acute disruption of blood supply to the optic nerve, leading to its damage and rapid vision loss.
Proposed Solution:
One of the promising approaches in treating these conditions is the use of citicoline, a natural metabolite that plays a key role in maintaining cellular membrane functions and neurotransmitter synthesis. Citicoline has a multifactorial mechanism of action, including:
- Phospholipid homeostasis: promotes the synthesis of phospholipids in neuronal membranes, ensuring their integrity and functionality.
- Mitochondrial dynamics: supports energy metabolism in cells, improving their viability.
- Cholinergic and dopaminergic transmission: increases neurotransmitter levels, enhancing nerve impulse transmission.
- Proteostasis regulation: interacts with the proteasome, helping maintain protein homeostasis in cells.
Recent studies indicate increased treatment efficacy for ophthalmic neurodegenerative diseases when citicoline is combined with platelet-rich plasma (PRP). PRP contains growth factors and cytokines that support tissue regeneration and the restoration of optic nerve functions.
The combination of PRP and citicoline can enhance the neuroprotective effect, improving treatment outcomes for conditions such as glaucoma, optic nerve atrophy, diabetic retinopathy, and anterior ischemic optic neuropathy (AION).
This combined therapy promotes the regeneration of damaged neurons, improves nerve impulse transmission, and strengthens overall visual functions. Using PRP along with citicoline can lead to faster and more effective vision recovery, reducing disease progression risks and improving patients’ quality of life.
Rationale for Use:
In addition to theoretical justifications, citicoline’s effectiveness has been confirmed by clinical studies. Specifically, in patients with open-angle glaucoma (OAG), citicoline has been shown to slow the progression of visual field defects. Improvements in psychophysical, morphological, and electrophysiological parameters have also been observed in patients with AION and diabetic retinopathy. These results highlight the potential of citicoline in comprehensive therapy for ophthalmic neurodegenerative diseases.
The Medical Expert team has extensive experience in applying combined PRP and citicoline therapy for treating ophthalmic neurodegenerative diseases. With a personalized approach and advanced treatment methods, we help patients achieve maximum vision restoration and improve their quality of life.
